| glucagon like peptide 1 receptor agonists | Decreases - have also been shown to reduce | body weight | Human | patients with type 2 diabetes | — | Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. |
| glp 1ras | Decreases - means a weight reduction of about | body weight | Human | patients | — | Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. |
| subcutaneous formulation of semaglutide | Decreases - reduced | body weight | Human | patients with type 2 diabetes | — | Semaglutide: First Global Approval. |
| semaglutide | Decreases - reduced | body weight | Human | patients with type 2 diabetes | — | A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. |
| glp 1 receptor agonists | Decreases - effective in reducing | body weight | Human | — | — | An overview of new GLP-1 receptor agonists for type 2 diabetes. |
| glucagon like peptide 1 receptor agonists | Decreases - positive effects on | body weight | Human | patients with type 2 diabetes | — | A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. |
| sodium glucose cotransporter 2 inhibitors | Decreases - positive effects on | body weight | Human | patients with type 2 diabetes | — | A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. |
| once weekly semaglutide 1.0 mg s.c. | Decreases - superior to exenatide ER 2.0 mg in reducing | body weight | Human | subjects with type 2 diabetes | — | Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. |
| sodium glucose cotransporter type 2 inhibitors | Decreases - favorably affect | body weight | Human | patients with type 2 diabetes | — | SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. |
| taspoglutide, 20 mg | Decreases - reduced | body weight | Human | adults with type 2 diabetes | — | Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. |
| once weekly exenatide | Decreases - reduced | body weight | Human | adults with type 2 diabetes | — | Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. |
| dulaglutide, 1.5 mg | Decreases - reduced | body weight | Human | adults with type 2 diabetes | — | Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. |
| taspoglutide, 20 mg | Decreases - reduced | body weight | Human | adults with type 2 diabetes | — | Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. |
| dulaglutide, 0.75 mg | Decreases - reduced | body weight | Human | adults with type 2 diabetes | — | Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. |
| taspoglutide, 20 mg | Decreases - showed a greater reduction | body weight | Human | adults with type 2 diabetes | — | Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. |
| glp 1r agonists | Decreases - reduce | body weight | Human | — | — | Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. |
| oral semaglutide | Decreases - reductions in body weight were greater | body weight | Human | patients with type 2 diabetes | — | Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. |
| subcutaneous semaglutide | Decreases - reductions in body weight were greater | body weight | Human | patients with type 2 diabetes | — | Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. |
| placebo | Decreases - reductions in body weight were greater | body weight | Human | patients with type 2 diabetes | — | Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. |
| oral semaglutide dosages of 10 mg or more | Decreases - significant for oral semaglutide dosages of 10 mg or more vs placebo | body weight | Human | patients with type 2 diabetes | — | Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. |
| glp 1 receptor agonists | Decreases - reduction | body weight | HumanMolecular | — | — | After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? |
| semaglutide 0.5 mg | Decreases - reduced | body weight | Human | Japanese people with type 2 diabetes (T2D) | — | Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. |
| semaglutide 1.0 mg | Decreases - reduced | body weight | Human | Japanese people with type 2 diabetes (T2D) | — | Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. |
| additional oad | Increases - increase | body weight | Human | Japanese people with type 2 diabetes (T2D) | — | Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. |
| semaglutide treatment | Decreases - significantly reduced | body weight | Human | Japanese people with T2D | — | Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. |
| once weekly s.c. semaglutide | Decreases - reduced | body weight | Human | Japanese adults with type 2 diabetes | — | Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. |
| once weekly s.c. semaglutide | Decreases - reduced | body weight | Human | Japanese adults with type 2 diabetes | — | Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. |
